Screener
Tango Therapeutics TNGX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchase of property and equipment | 2 | (51) |
| Sales and maturities of marketable securities | 64,045 | 77,812 |
| Purchases of marketable securities | (54,412) | (47,164) |
| Net cash provided by investing activities | 9,635 | 30,597 |
| Cash flows from financing activities | ||
| Proceeds from at-the-market offerings, net of issuance costs | 62,778 | — |
| Payment of transaction costs | (537) | — |
| Proceeds from issuance of common stock under stock plans | 17,605 | 2 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's investing cash flow?
- Tango Therapeutics (TNGX) reported investing cash flow of $9.64M in Q1 2026.
- How has Tango Therapeutics's investing cash flow changed year-over-year?
- Tango Therapeutics's investing cash flow decreased by 68.5% year-over-year, from $30.6M to $9.64M.
- What is the long-term trend for Tango Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Tango Therapeutics's investing cash flow has grown at a -52.8% compound annual growth rate (CAGR), from -$183.43M to -$40.87M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Tango Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude